38 filings
Page 2 of 2
8-K
0kb0dqg0pql jxa433o
22 Feb 23
Cognition Therapeutics and ACTC Receive FDA Clearance for Phase 2 START Study of Oral CT1812 in Early Alzheimer’s Disease
8:14am
8-K
snsrzv 40071n
13 Feb 23
Other Events
8:00am
8-K
mqjshhikc7
23 Dec 22
Entry into a Material Definitive Agreement
4:24pm
8-K
ntvb u7ua
16 Nov 22
Developing disease - modifying medicines for degenerative disorders November 2022
5:18pm
8-K
y4buiboj5n3b adlhd
14 Nov 22
Cognition Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update
8:00am
8-K
m1ve8r1mawg4t 17oh
29 Aug 22
Developing disease- modifying medicines for degenerative disorders August 2022
6:36am
8-K
hjhq7qq
9 Aug 22
Cognition Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update
7:15am
8-K
qegvtoor
27 Jul 22
Departure of Directors or Certain Officers
4:30pm
8-K
f4i9l
16 Jun 22
Regulation FD Disclosure
7:08am
8-K
cz8b9v 8q
13 Jun 22
Submission of Matters to a Vote of Security Holders
5:07pm
8-K
fcoqx
11 May 22
Cognition Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update
7:06am
8-K
85eyte
30 Mar 22
Cognition Therapeutics Reports Year End 2021 Financial Results and Provides
7:29am
8-K
j9zhatv 9ka
15 Mar 22
Regulation FD Disclosure
9:32am
8-K
2hidv
10 Jan 22
Regulation FD Disclosure
7:01am
8-K
s3k0r rrt884xkr3zu
18 Nov 21
Cognition Therapeutics Reports Third Quarter Financial Results and Company Highlights
8:30am
8-K
ycuma826
12 Nov 21
Regulation FD Disclosure
5:20pm
8-K
fet14psvf2r
3 Nov 21
Departure of Directors or Certain Officers
4:25pm
8-K
sqi81asa1gypwv7uy9
14 Oct 21
Amendments to Articles of Incorporation or Bylaws
4:41pm